WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Cancer Research and Clinical Oncology

• Publication date

  2013-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00432-012-1348-2PMID 23160854PMCID PMC11824617
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.

  2011cited by this paper
• WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient

  2010cited by this paper
• WT1 peptide immunotherapy for cancer in children and young adults

  2010cited by this paper
• Effects of third-line chemotherapy for women with recurrent ovarian cancer who received platinum/taxane regimens as first-line chemotherapy.

  2010cited by this paper
• WT1 peptide vaccine, one of the most promising cancer vaccines: its present status and the future prospects.

  2010cited by this paper
• Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.

  2009cited by this paper
• New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

  2009cited by this paper
• Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer.

  2009cited by this paper
• The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

  2009cited by this paper
• Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.

  2008cited by this paper
• Topotecan and carboplatin in patients with platinum-sensitive recurrent ovarian cancer. Results of a multicenter NOGGO: phase I/II study

  2008cited by this paper
• A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data.

  2006cited by this paper
• Treatment of recurrent ovarian cancer: a retrospective analysis of women treated with single-agent carboplatin originally treated with carboplatin and paclitaxel. The Memorial Sloan-Kettering Cancer Center experience.

  2003cited by this paper
• Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.

  2003cited by this paper
• Part II: chemotherapy for epithelial ovarian cancer-treatment of recurrent disease.

  2002cited by this paper
• Clinical Gynecologic Oncology

  1981cited by this paper

• Nucleic acid‐based vaccine for ovarian cancer cells; bench to bedside

  2024cites this paper
• Peptide Vaccines as Therapeutic and Prophylactic Agents for Female-Specific Cancers: The Current Landscape

  2023cites this paper
• Maveropepimut-S, a DPX-Based Immune-Educating Therapy, Shows Promising and Durable Clinical Benefit in Patients with Recurrent Ovarian Cancer, a Phase II Trial

  2023cites this paper
• Mechanism of action of DSP-7888 (adegramotide/nelatimotide) Emulsion, a peptide-based therapeutic cancer vaccine with the potential to turn up the heat on non-immunoreactive tumors

  2022cites this paper
• WT1 epitope-specific IgG and IgM antibodies for immune-monitoring in patients with advanced sarcoma treated with a WT1 peptide cancer vaccine

  2022cites this paper
• Peptide-Based Nanovaccines in the Treatment of Cervical Cancer: A Review of Recent Advances

  2022cites this paper
• Potential association factors for developing effective peptide-based cancer vaccines

  2022cites this paper
• Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment

  2021cites this paper
• Immunotherapy in endometrial cancer: rationale, practice and perspectives

  2021cites this paper
• Identification of mouse helper epitopes for WT1-specific CD4+ T cells

  2021cites this paper
• Cellular and Humoral Immune Responses Induced by an HLA Class I–restricted Peptide Cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian Cancer

  2021cites this paper
• Evaluation of the incidence and clinical significance of WT-1 expression in uterine serous carcinoma

  2021cites this paper
• Development of Therapeutic Vaccines for Ovarian Cancer

  2020cites this paper
• Synthetic, Supramolecular, and Self‐Adjuvanting CD8+ T‐Cell Epitope Vaccine Increases the Therapeutic Antitumor Immunity

  2019cites this paper
• Immune adjuvant therapy using Bacillus Calmette–Guérin cell wall skeleton (BCG-CWS) in advanced malignancies

  2019cites this paper
• Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer.

  2018cites this paper
• Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer

  2018cites this paper
• WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer

  2018cites this paper
• The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy

  2018cites this paper
• Combination Gemcitabine and WT1 Peptide Vaccination Improves Progression-Free Survival in Advanced Pancreatic Ductal Adenocarcinoma: A Phase II Randomized Study

  2018cites this paper
• Peptide Delivery Systems for Cancer Vaccines

  2018cites this paper
• Cancer vaccine therapy based on peptides

  2017cites this paper
• WT1 Peptide Vaccine for the Treatment of Malignancies: Its Development, Recent Progress, and Future Perspectives

  2016cites this paper
• Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade

  2016cites this paper
• Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine

  2016cites this paper
• Immunotherapy Targeting WT1: Designing a Protocol for WT1 Peptide-Based Cancer Vaccine.

  2016cites this paper
• Good Response to Chemotherapy Spares Irradiation for Extrarenal Rhabdoid Tumor Conferring Better Activities of Daily Living

  2015cites this paper
• Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer

  2015cites this paper
• Two distinct effector memory cell populations of WT1 (Wilms’ tumor gene 1)-specific cytotoxic T lymphocytes in acute myeloid leukemia patients

  2015cites this paper
• The WT1-gene – its role in tumourigenesis and prospects for developing a vaccine

  2014cites this paper
• Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

  2014cites this paper
• Wilms' tumor gene 1 immunotherapy in pelvic gynecological malignancies

  2014cites this paper
• Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer

  2014cites this paper
• WT1-, PRAME- and MSLN- specific immunity in epithelial ovarian cancer

  2014cites this paper
• Trial Watch

  2013cites this paper
• Wilms' Tumor Gene 1 (WT1)--loaded dendritic cell immunotherapy in patients with uterine tumors: a phase I/II clinical trial.

  2013cites this paper
• Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma.

  2013cites this paper
• Trial watch

  2012cites this paper